Meiji Yasuda Life Insurance Co Decreases Holdings in Astera Labs, Inc. $ALAB

Meiji Yasuda Life Insurance Co lowered its holdings in Astera Labs, Inc. (NASDAQ:ALAB) by 62.1% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 1,950 shares of the company’s stock after selling 3,200 shares during the quarter. Meiji Yasuda Life Insurance Co’s holdings in Astera Labs were worth $942,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. BlackRock Inc. acquired a new position in Astera Labs in the second quarter valued at approximately $6,609,581,000. Bank of America Corp DE purchased a new position in Astera Labs in the second quarter valued at approximately $1,061,791,000. Atreides Management LP raised its holdings in Astera Labs by 108.9% during the first quarter. Atreides Management LP now owns 3,365,787 shares of the company’s stock worth $368,890,000 after purchasing an additional 1,754,593 shares in the last quarter. Amundi raised its holdings in Astera Labs by 1,298.6% during the third quarter. Amundi now owns 1,421,263 shares of the company’s stock worth $278,283,000 after purchasing an additional 1,319,643 shares in the last quarter. Finally, Artisan Partners Limited Partnership purchased a new stake in shares of Astera Labs during the 4th quarter worth approximately $148,980,000. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Buying and Selling at Astera Labs

In related news, Director Manuel Alba sold 136,974 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $442.01, for a total value of $60,543,877.74. Following the transaction, the director owned 1,287,524 shares in the company, valued at $569,098,483.24. The trade was a 9.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Sanjay Gajendra sold 90,630 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $340.35, for a total value of $30,845,920.50. Following the sale, the chief operating officer directly owned 1,119,038 shares of the company’s stock, valued at approximately $380,864,583.30. This represents a 7.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 419,244 shares of company stock valued at $163,135,169. Corporate insiders own 10.40% of the company’s stock.

Astera Labs Price Performance

Shares of Astera Labs stock opened at $289.47 on Friday. The firm’s fifty day simple moving average is $342.38 and its 200-day simple moving average is $249.65. The stock has a market capitalization of $50.22 billion, a price-to-earnings ratio of 143.30 and a beta of 3.84. Astera Labs, Inc. has a 12 month low of $97.89 and a 12 month high of $499.48.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings results on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.69 by $0.11. Astera Labs had a net margin of 30.74% and a return on equity of 19.24%. The firm had revenue of $392.40 million during the quarter, compared to the consensus estimate of $360.85 million. During the same quarter in the prior year, the firm earned $0.44 EPS. Astera Labs’s revenue for the quarter was up 104.5% on a year-over-year basis. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. Analysts anticipate that Astera Labs, Inc. will post 2.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ALAB has been the subject of several research analyst reports. Barclays upped their target price on shares of Astera Labs from $200.00 to $325.00 and gave the company an “equal weight” rating in a report on Monday, July 20th. Zacks Research raised shares of Astera Labs from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, August 11th. Evercore restated an “outperform” rating and issued a $297.00 price objective on shares of Astera Labs in a research note on Tuesday, May 19th. Needham & Company LLC raised their price objective on Astera Labs from $260.00 to $425.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Finally, Royal Bank Of Canada lifted their target price on Astera Labs from $425.00 to $500.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have issued a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $340.53.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.